Condition: Alport Syndrome · Focal Segmental Glomerulosclerosis · Sponsor: River 3 Renal Corp.
This is a Phase 2, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Investigative Site | Los Angeles, California, United States | — |
| Investigative site | Boca Raton, Florida, United States | — |
| Investigative site | Miami, Florida, United States | — |
| Investigative site | Riverview, Florida, United States | — |
| Investigative site | Atlanta, Georgia, United States | — |
| Investigative site | Boston, Massachusetts, United States | — |
| Investigative site | Ann Arbor, Michigan, United States | — |
| Investigative site | Minneapolis, Minnesota, United States | — |
| Investigative Site | Cary, North Carolina, United States | — |
| Investigative site | Cleveland, Ohio, United States | — |
| Investigative site | Columbus, Ohio, United States | — |
| Investigative site | East Providence, Rhode Island, United States | — |
+ 10 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05267262